MedTrace Logo

Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

NCT02011386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2020-08-17

Study results available
· View outcomes & findings →

Summary

The study investigates different criteria for remission based on MRI and circulating biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates factors that affect disease activity, function and participation by use of different questionnaires.

Conditions

  • Axial Spondyloarthritis

Interventions

DRUG

Treatment

Sponsors & Collaborators

Principal Investigators

  • Mikkel Østergaard, Professor · Glostrup Hospital, University of Copenhagen

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2017-02-14
Completion
2017-02-14

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02011386 on ClinicalTrials.gov